Normal inflammatory markers in giant cell arteritis with long-standing cranial and symptomatic large-vessel involvement

We report the case of a 78-year-old woman who presented with cardiovascular risk factors and a history of an atypical transient ischaemic attack. She was referred by her primary care physician to the vascular surgery department at our institution for evaluation of progressive weakness, fatigue, arm claudication and difficulty assessing the blood pressure in her right arm. She was being considered for surgical revascularisation, but a careful history and review of her imaging studies raised suspicion for vasculitis, despite her normal inflammatory markers. She was eventually diagnosed with biopsy-proven giant cell arteritis with diffuse large-vessel involvement. Her symptoms improved with high-dose glucocorticoids.

[1]  J. Fonseca,et al.  Giant cell arteritis with normal inflammatory markers: case report and review of the literature , 2020, Clinical Rheumatology.

[2]  T. Ruddy,et al.  PET/CT for Diagnosis and Management of Large-Vessel Vasculitis , 2019, Current Cardiology Reports.

[3]  D. Metze,et al.  Nomenclature of cutaneous vasculitides – German translation of the dermatologic addendum to the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides , 2018, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[4]  E. Matteson,et al.  The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease , 2016, Rheumatology.

[5]  E. Matteson,et al.  Visual Manifestations in Giant Cell Arteritis: Trend over 5 Decades in a Population-based Cohort , 2015, The Journal of Rheumatology.

[6]  G. Hunder,et al.  Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis. , 2012, Seminars in arthritis and rheumatism.

[7]  D A Bloch,et al.  The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. , 2010, Arthritis and rheumatism.

[8]  H. Raspe,et al.  EULAR recommendations for the management of large vessel vasculitis , 2008, Annals of the rheumatic diseases.

[9]  M. Vilardell‐Tarrés,et al.  Proposal to decrease the number of negative temporal artery biopsies , 2007, Scandinavian journal of rheumatology.

[10]  H. Spiera,et al.  Inflammatory disease in older adults. Cranial arteritis. , 2004, Geriatrics.

[11]  S. Hayreh,et al.  Occult giant cell arteritis: ocular manifestations. , 1998, American journal of ophthalmology.

[12]  G. Dutton,et al.  Current concepts in giant cell (temporal) arteritis. , 1997, Survey of ophthalmology.

[13]  Welton Rc,et al.  Temporal arteritis presenting with jaw claudication and normal erythrocyte sedimentation rate. , 1982 .

[14]  J. Toole,et al.  Temporal arteritis associated with normal sedimentation rate. , 1982, JAMA.

[15]  L. Espinoza,et al.  Temporal arteritis with normal ESR. , 1980, Archives of internal medicine.

[16]  P. Newman Giant cell arteritis with normal sedimentation rate. , 1978, Archives of neurology.

[17]  A. D. Bull,et al.  How common is inflammatory marker-negative disease in giant cell arteritis? , 2013, Eye.

[18]  P. Merkel,et al.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. , 2013, Arthritis and rheumatism.

[19]  D. Formisano,et al.  Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. , 2009, Rheumatology.

[20]  A. de la Sierra,et al.  Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. , 1998, Arthritis and rheumatism.